You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pembrolizumab

Showing 26 - 50 of 2,041
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial (GME751, Keytruda - EU, Keytruda - US)

Not yet recruiting
  • Melanoma
  • (no location specified)
Nov 22, 2023

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Pembrolizumab
  • +7 more
  • Beijing, Beijing, China
    Beijing Tongren Hospital
Oct 26, 2023

Melanoma Trial in Nedlands, Haifa, Jerusalem (Pembrolizumab/Vibostolimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Pembrolizumab/Vibostolimab
  • Pembrolizumab
  • Nedlands, Western Australia, Australia
  • +2 more
Jan 31, 2023

GastroEsophageal Cancer, Gastric Cancer Trial in Tampa (Neratinib, Trastuzumab, Oxaliplatin)

Recruiting
  • GastroEsophageal Cancer
  • Gastric Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Oct 25, 2023

Cholangiocarcinoma Trial in Houston (Pembrolizumab, Gemcitabine, Cisplatin)

Not yet recruiting
  • Cholangiocarcinoma
  • Pembrolizumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2023

Metastatic NSCLC Trial (Pembrolizumab coformulated with hyaluronidase, Pemetrexed, Cisplatin)

Not yet recruiting
  • Metastatic Non-small Cell Lung Cancer
  • Pembrolizumab coformulated with hyaluronidase
  • +6 more
  • (no location specified)
Jan 27, 2023

Stage IIIA NSCLC Trial in Cleveland (Cisplatin, Etoposide, Pembrolizumab)

Terminated
  • Stage IIIA Non-Small Cell Lung Cancer
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Dec 15, 2022

Urothelial Carcinoma Trial in New York (Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab)

Not yet recruiting
  • Urothelial Carcinoma
  • Naptumomab Estafenatox
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
May 30, 2023

Head and Neck Tumors Trial (TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 ß/?)

Not yet recruiting
  • Head and Neck Neoplasms
  • TransCon TLR7/8 Agonist
  • +2 more
  • (no location specified)
Aug 4, 2023

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • Pembrolizumab
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 18, 2023

Bladder Cancer Trial (pembrolizumab)

Active, not recruiting
  • Bladder Cancer
  • Pembrolizumab
  • +2 more
  • (no location specified)
Oct 11, 2022

Soft Tissue Sarcoma Trial (pembrolizumab, pazopanib)

Not yet recruiting
  • Soft Tissue Sarcoma
  • pembrolizumab, pazopanib
  • (no location specified)
Dec 26, 2022

Kaposi Sarcoma, Classic Kaposi Sarcoma, Refractory Kaposi Sarcoma Trial (Pembrolizumab + Lenvatinib)

Not yet recruiting
  • Kaposi Sarcoma
  • +2 more
  • Pembrolizumab + Lenvatinib
  • (no location specified)
Apr 27, 2023

Renal Cell Carcinoma Trial in Philadelphia (Pembrolizumab infusion, Lenvatinib tablet)

Not yet recruiting
  • Renal Cell Carcinoma
  • Pembrolizumab infusion
  • Lenvatinib tablet
  • Philadelphia, Pennsylvania
    Abramson Cancer Center at University of Pennsylvania
Feb 8, 2023

NSCLC, Melanoma Trial (IMM60, Pembrolizumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Melanoma
  • (no location specified)
Jan 24, 2023

Merkel Cell Carcinoma Trial in Milano, Siena, Verona (Pembrolizumab, Etoposide, Cisplatin or Carboplatin)

Not yet recruiting
  • Merkel Cell Carcinoma
  • Pembrolizumab, Etoposide, Cisplatin or Carboplatin
  • Milano, Italy
  • +2 more
Oct 10, 2023

Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib Trial in Taipei City (Lenvatinib/Pembrolizumab plus SBRT

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • +3 more
  • Lenvatinib/Pembrolizumab plus SBRT combinations
  • Taipei City, Taiawn, Taiwan
    National Taiwan University Hospital
Jan 30, 2023

Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors Trial run by the National

Not yet recruiting
  • Adenocarcinoma of the Bladder
  • +2 more
  • Enfortumab vedotin
  • Pembrolizumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Sep 22, 2023

Solid Tumors Trial in Charlottesville (XmAb662, Keytruda® (pembrolizumab))

Recruiting
  • Solid Tumors
  • XmAb662
  • Keytruda® (pembrolizumab)
  • Charlottesville, Virginia
    University Of Virginia Comprehensive Cancer Center
Aug 10, 2023

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023

Lung Non-Small Cell Carcinoma Trial in Buffalo (Pembrolizumab)

Active, not recruiting
  • Lung Non-Small Cell Carcinoma
  • Pembrolizumab
  • Buffalo, New York
    Roswell Park Cancer Institute
Jan 27, 2023

Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer Trial in Nashville (drug, biological,

Not yet recruiting
  • Limited Stage Lung Small Cell Carcinoma
  • +3 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Nov 10, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Head and Neck Squamous Cell Carcinoma Trial in Baltimore (Pembrolizumab, IO102-103)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Baltimore, Maryland
    Johns Hopkins University
Aug 2, 2023

Renal Cell Carcinoma Trial (Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy,

Not yet recruiting
  • Renal Cell Carcinoma
  • Neoadjuvant Lenvatinib
  • +3 more
  • (no location specified)
Dec 23, 2022